Intraoperative Mannitol Not Essential during Partial Nephrectomy

Caleb A. Cooper, Cheuk Fan Shum, Clinton Bahler, Chandru Sundaram

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: Intraoperative mannitol is routinely administered for renoprotection in partial nephrectomy (PN). However, there is a paucity of evidence supporting mannitol's renoprotective effect. We performed a retrospective study of mannitol's efficacy in PN. Materials and Methods: Using an institutional database, patients undergoing PN from 2006 to 2016 were retrospectively identified and divided into two groups based on mannitol use. Cases with missing serum creatinine measurements were excluded. Mannitol use was dependent on surgeon preference. An independent-samples t-test was used to compare 6-month postoperative estimated glomerular filtration rate (eGFR) between mannitol groups and to compare 6-month eGFR between mannitol dose for patients who received mannitol. Multivariate linear regression was used to estimate 6-month eGFR when adjusting for multiple covariates that were considered clinically relevant to postoperative renal function. Results: Of the patients, 476 patients were eligible for analysis and 286 received mannitol. Preoperative eGFR (7.8 ± 21.4 mL/minute/1.73 m 2 vs 75.3 ± 23.1 mL/minute/1.73 m 2, p = 0.223) and tumor size (3.5 ± 1.7 cm vs 3.4 ± 1.5 cm, p = 0.532) were matched between the mannitol (M+) and no mannitol (M groups, whereas warm ischemic time (22.5 ± 11.2 minutes vs 15.0 ± 10.2 minutes, p < 0.001) was longer in the M+ group. There was no significant difference in 6-month eGFR between mannitol groups (70.6 ± 22.2 mL/minute/1.73 m 2 vs 68.0 ± 23.9 mL/minute/1.73 m 2, p = 0.225). No significant association between mannitol dose and 6-month eGFR was found. Covariates that significantly predicted 6-month eGFR in our multivariate model were age (β = 0.052, p = 0.042) and preoperative eGFR (β = 0.843, p < 0.001). In addition, neither the use of renal cooling nor the surgical approach (open vs minimally invasive) was significantly associated with 6-month eGFR. Conclusion: Mannitol did not demonstrate renoprotective effects based on analysis of 6-month postoperative eGFR. In addition, neither the surgical approach nor the use of renal cooling significantly predicted postoperative renal function.

Original languageEnglish (US)
Pages (from-to)354-358
Number of pages5
JournalJournal of Endourology
Volume32
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

Mannitol
Nephrectomy
Glomerular Filtration Rate
Kidney
Warm Ischemia
Linear Models
Creatinine
Retrospective Studies

Keywords

  • partial nephrectomy, mannitol, renal cancer, renal function

ASJC Scopus subject areas

  • Urology

Cite this

Intraoperative Mannitol Not Essential during Partial Nephrectomy. / Cooper, Caleb A.; Shum, Cheuk Fan; Bahler, Clinton; Sundaram, Chandru.

In: Journal of Endourology, Vol. 32, No. 4, 01.04.2018, p. 354-358.

Research output: Contribution to journalArticle

@article{f770437e795a4a24a43574235bf18417,
title = "Intraoperative Mannitol Not Essential during Partial Nephrectomy",
abstract = "Objective: Intraoperative mannitol is routinely administered for renoprotection in partial nephrectomy (PN). However, there is a paucity of evidence supporting mannitol's renoprotective effect. We performed a retrospective study of mannitol's efficacy in PN. Materials and Methods: Using an institutional database, patients undergoing PN from 2006 to 2016 were retrospectively identified and divided into two groups based on mannitol use. Cases with missing serum creatinine measurements were excluded. Mannitol use was dependent on surgeon preference. An independent-samples t-test was used to compare 6-month postoperative estimated glomerular filtration rate (eGFR) between mannitol groups and to compare 6-month eGFR between mannitol dose for patients who received mannitol. Multivariate linear regression was used to estimate 6-month eGFR when adjusting for multiple covariates that were considered clinically relevant to postoperative renal function. Results: Of the patients, 476 patients were eligible for analysis and 286 received mannitol. Preoperative eGFR (7.8 ± 21.4 mL/minute/1.73 m 2 vs 75.3 ± 23.1 mL/minute/1.73 m 2, p = 0.223) and tumor size (3.5 ± 1.7 cm vs 3.4 ± 1.5 cm, p = 0.532) were matched between the mannitol (M+) and no mannitol (M groups, whereas warm ischemic time (22.5 ± 11.2 minutes vs 15.0 ± 10.2 minutes, p < 0.001) was longer in the M+ group. There was no significant difference in 6-month eGFR between mannitol groups (70.6 ± 22.2 mL/minute/1.73 m 2 vs 68.0 ± 23.9 mL/minute/1.73 m 2, p = 0.225). No significant association between mannitol dose and 6-month eGFR was found. Covariates that significantly predicted 6-month eGFR in our multivariate model were age (β = 0.052, p = 0.042) and preoperative eGFR (β = 0.843, p < 0.001). In addition, neither the use of renal cooling nor the surgical approach (open vs minimally invasive) was significantly associated with 6-month eGFR. Conclusion: Mannitol did not demonstrate renoprotective effects based on analysis of 6-month postoperative eGFR. In addition, neither the surgical approach nor the use of renal cooling significantly predicted postoperative renal function.",
keywords = "partial nephrectomy, mannitol, renal cancer, renal function",
author = "Cooper, {Caleb A.} and Shum, {Cheuk Fan} and Clinton Bahler and Chandru Sundaram",
year = "2018",
month = "4",
day = "1",
doi = "10.1089/end.2017.0415",
language = "English (US)",
volume = "32",
pages = "354--358",
journal = "Journal of Endourology",
issn = "0892-7790",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Intraoperative Mannitol Not Essential during Partial Nephrectomy

AU - Cooper, Caleb A.

AU - Shum, Cheuk Fan

AU - Bahler, Clinton

AU - Sundaram, Chandru

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Objective: Intraoperative mannitol is routinely administered for renoprotection in partial nephrectomy (PN). However, there is a paucity of evidence supporting mannitol's renoprotective effect. We performed a retrospective study of mannitol's efficacy in PN. Materials and Methods: Using an institutional database, patients undergoing PN from 2006 to 2016 were retrospectively identified and divided into two groups based on mannitol use. Cases with missing serum creatinine measurements were excluded. Mannitol use was dependent on surgeon preference. An independent-samples t-test was used to compare 6-month postoperative estimated glomerular filtration rate (eGFR) between mannitol groups and to compare 6-month eGFR between mannitol dose for patients who received mannitol. Multivariate linear regression was used to estimate 6-month eGFR when adjusting for multiple covariates that were considered clinically relevant to postoperative renal function. Results: Of the patients, 476 patients were eligible for analysis and 286 received mannitol. Preoperative eGFR (7.8 ± 21.4 mL/minute/1.73 m 2 vs 75.3 ± 23.1 mL/minute/1.73 m 2, p = 0.223) and tumor size (3.5 ± 1.7 cm vs 3.4 ± 1.5 cm, p = 0.532) were matched between the mannitol (M+) and no mannitol (M groups, whereas warm ischemic time (22.5 ± 11.2 minutes vs 15.0 ± 10.2 minutes, p < 0.001) was longer in the M+ group. There was no significant difference in 6-month eGFR between mannitol groups (70.6 ± 22.2 mL/minute/1.73 m 2 vs 68.0 ± 23.9 mL/minute/1.73 m 2, p = 0.225). No significant association between mannitol dose and 6-month eGFR was found. Covariates that significantly predicted 6-month eGFR in our multivariate model were age (β = 0.052, p = 0.042) and preoperative eGFR (β = 0.843, p < 0.001). In addition, neither the use of renal cooling nor the surgical approach (open vs minimally invasive) was significantly associated with 6-month eGFR. Conclusion: Mannitol did not demonstrate renoprotective effects based on analysis of 6-month postoperative eGFR. In addition, neither the surgical approach nor the use of renal cooling significantly predicted postoperative renal function.

AB - Objective: Intraoperative mannitol is routinely administered for renoprotection in partial nephrectomy (PN). However, there is a paucity of evidence supporting mannitol's renoprotective effect. We performed a retrospective study of mannitol's efficacy in PN. Materials and Methods: Using an institutional database, patients undergoing PN from 2006 to 2016 were retrospectively identified and divided into two groups based on mannitol use. Cases with missing serum creatinine measurements were excluded. Mannitol use was dependent on surgeon preference. An independent-samples t-test was used to compare 6-month postoperative estimated glomerular filtration rate (eGFR) between mannitol groups and to compare 6-month eGFR between mannitol dose for patients who received mannitol. Multivariate linear regression was used to estimate 6-month eGFR when adjusting for multiple covariates that were considered clinically relevant to postoperative renal function. Results: Of the patients, 476 patients were eligible for analysis and 286 received mannitol. Preoperative eGFR (7.8 ± 21.4 mL/minute/1.73 m 2 vs 75.3 ± 23.1 mL/minute/1.73 m 2, p = 0.223) and tumor size (3.5 ± 1.7 cm vs 3.4 ± 1.5 cm, p = 0.532) were matched between the mannitol (M+) and no mannitol (M groups, whereas warm ischemic time (22.5 ± 11.2 minutes vs 15.0 ± 10.2 minutes, p < 0.001) was longer in the M+ group. There was no significant difference in 6-month eGFR between mannitol groups (70.6 ± 22.2 mL/minute/1.73 m 2 vs 68.0 ± 23.9 mL/minute/1.73 m 2, p = 0.225). No significant association between mannitol dose and 6-month eGFR was found. Covariates that significantly predicted 6-month eGFR in our multivariate model were age (β = 0.052, p = 0.042) and preoperative eGFR (β = 0.843, p < 0.001). In addition, neither the use of renal cooling nor the surgical approach (open vs minimally invasive) was significantly associated with 6-month eGFR. Conclusion: Mannitol did not demonstrate renoprotective effects based on analysis of 6-month postoperative eGFR. In addition, neither the surgical approach nor the use of renal cooling significantly predicted postoperative renal function.

KW - partial nephrectomy, mannitol, renal cancer, renal function

UR - http://www.scopus.com/inward/record.url?scp=85045845142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045845142&partnerID=8YFLogxK

U2 - 10.1089/end.2017.0415

DO - 10.1089/end.2017.0415

M3 - Article

VL - 32

SP - 354

EP - 358

JO - Journal of Endourology

JF - Journal of Endourology

SN - 0892-7790

IS - 4

ER -